Case Summary: Karyopharm Therapeutics Chapter 11
Karyopharm Therapeutics filed for Chapter 11 with a prepackaged plan to equitize about $276 million of secured funded debt into up to 55% of a combined company with Ayrmid, subject to competing bids, after payment defaults and what it calls mixed Phase 3 results.